Dynamic Changes of Circulating Tumor DNA in Surgical Lung Cancer Patients

Status Completed

Clinical Trial Summary

Previous study showed circulating tumor DNA levels reflect the total systemic tumor burden. Circulating tumor DNA levels should decrease after complete surgery and could be increase as tumor recurrence. Few study investigated the half time of circulating tumor DNA in lung cancer patients that no criterion has been established of how to use it for surveillance.

Clinical Trial Description

For lung cancer patients who received surgery, multiple time of plasma will be collected before or after surgery. A series of mutations will be detected in plasma before surgery based on next generation sequencing. The positive mutation will be traced after surgery and in follow up. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02965391
Study type	Observational [Patient Registry]
Source	Peking University People's Hospital
Contact
Status	Completed
Phase
Start date	November 2016
Completion date	November 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03357094` - Pulmonary Ventilation/Perfusion Imaging for the Prediction of Postoperative Residual Pulmonary Function	N/A
Recruiting	`NCT05543954` - 68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients	Early Phase 1
Completed	`NCT01114958` - Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases	Phase 1
Recruiting	`NCT06004440` - Real World Registry for Use of the Ion Endoluminal System
Not yet recruiting	`NCT02907606` - Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study	N/A
Completed	`NCT02926768` - Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT02514512` - Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking	N/A
Completed	`NCT02531737` - Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer	Phase 2
Completed	`NCT02334007` - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery	Phase 1/Phase 2
Active, not recruiting	`NCT02284633` - Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer
Completed	`NCT02106143` - RejuvenAir™ System Lobectomy Safety and Histology Study	N/A
Completed	`NCT01933789` - Improving Communication About Serious Illness	N/A
Enrolling by invitation	`NCT01687647` - Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure	Phase 3
Completed	`NCT00243685` - Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis	Phase 2/Phase 3
Completed	`NCT00351962` - Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours	N/A
Terminated	`NCT00356525` - Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor	Phase 2
Completed	`NCT00385177` - Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT00129844` - Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer	Phase 2
Withdrawn	`NCT00090701` - A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer	Phase 2
Recruiting	`NCT01789229` - Establishment of a Tumor Bank for Tissue Samples